Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Management will also be available for one-on-one meetings. Details are as follows:

Piper Sandler 34th Annual Healthcare Conference

Date: Wednesday, November 30
Time: 4:00 p.m. ET
Location: The Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005149/en/

Syros Contact
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
[email protected]

Media Contact
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-813-767-7801
[email protected]

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Source: Syros Pharmaceuticals

You May Also Be Interested In

• ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
• Sui Price Prediction: Can SUI Hit $5 as Next Crypto To Explode AlphaPepe Builds Four Products Pre-Launch?
• Best Crypto Presale as the Market Cools: $BULLSKI Did Not Reprice